“Conclusion: In patients with MASH who achieve a ≥10% weight loss, GLP-1RAs and dual agonists are associated with significant improvements in hepatic fibrosis, whereas their effect is limited in those with <10% weight loss. However, a significant reduction in LDL-C was observed only among patients achieving substantial (≥10%) weight loss. This finding suggests that for patients requiring comprehensive cardiovascular risk management, additional lipid-lowering strategies may be needed to optimize the effectiveness of the intervention.”
Here’s a summary of the paper “Comparative effectiveness of GLP-1 receptor agonists and dual agonists in the treatment of patients with metabolic dysfunction associated steatohepatitis: a systematic review and meta-analysis” by Li et al (2025).
Background
- The authors conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating GLP-1 receptor agonists (GLP-1 RAs) and dual agonists in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH).
- They highlight that while these agents have shown histologic improvement in MASH, evidence regarding improvement in hepatic fibrosis and cardiovascular (CV) outcomes remains inconsistent.
Methods
- The search included major databases up to August 30, 2025, focusing on patients with biopsy-confirmed MASH.
- Six RCTs met inclusion criteria, encompassing 1,726 patients.
- Outcomes included: histological improvement of MASH without worsening fibrosis; ≥1-stage improvement in hepatic fibrosis without worsening MASH; combined histologic resolution and fibrosis improvement; and secondary outcomes like lipid parameters.
Results
- Treatment with GLP-1RAs/dual agonists versus placebo significantly increased the likelihood of histological improvement of MASH without worsening fibrosis (OR = 4.51; 95% CI 3.68–5.52).
- They also found a statistically significant improvement in ≥1-stage hepatic fibrosis improvement without worsening MASH (OR = 1.78; 95% CI 1.47–2.16).
- For the combined outcome — MASH resolution + ≥1-stage fibrosis improvement — OR was 7.42 (95% CI 2.98–18.48).
- Importantly, in subgroup analysis by weight-loss achieved:
- In patients achieving ≥10% weight loss, the benefit for fibrosis improvement without worsening MASH was strong (OR = 9.59; 95% CI 4.01–15.18).
- In patients with <10% weight loss, the effect was not statistically significant (OR = 1.30; 95% CI 0.92–1.83).
- Regarding lipid outcomes: total cholesterol and triglycerides were significantly reduced (WMD for TC ~ –4.15 mmol/L; TG ~ –17.70 mmol/L).
- LDL-cholesterol (LDL-C) did not show a statistically significant improvement overall (WMD = –0.67 mmol/L; 95% CI –6.55 to 5.21).
Implications
- The authors conclude that for patients with MASH, GLP-1RAs and dual agonists are associated with meaningful improvements in histologic features — particularly if substantial weight loss (≥10%) is achieved.
- They note that in patients with less than 10% weight loss the benefit is limited. They also flag that despite lipid improvements (TC, TG), LDL-C did not significantly improve—meaning additional strategies may be needed when optimizing cardiovascular risk in this population.
- They suggest weight loss remains a key mediator of benefit from these agents in MASH with respect to fibrosis improvement.
Considerations
- The meta-analysis is necessarily limited by the number of RCTs (six) and their individual designs; heterogeneity may exist though the authors used appropriate models.
- Weight loss appears to be a mediator of efficacy — meaning the pharmacologic benefit may depend significantly on achieving an adequate weight-loss target, so results may not translate to all patients equally.
- The cardiovascular lipid outcomes are supportive but incomplete (LDL-C not improved meaningfully) so one should not assume full CV benefit just from these therapies in MASH.
- Long-term outcomes (hard endpoints: liver decompensation, transplant, CV events) are not addressed in depth.